MA32727B1 - Pyrazolylaminopyridines au titre d'inhibiteurs de fak - Google Patents

Pyrazolylaminopyridines au titre d'inhibiteurs de fak

Info

Publication number
MA32727B1
MA32727B1 MA33791A MA33791A MA32727B1 MA 32727 B1 MA32727 B1 MA 32727B1 MA 33791 A MA33791 A MA 33791A MA 33791 A MA33791 A MA 33791A MA 32727 B1 MA32727 B1 MA 32727B1
Authority
MA
Morocco
Prior art keywords
pyrazolylaminoperidine
fak inhibitors
fak
inhibitors
cancer
Prior art date
Application number
MA33791A
Other languages
Arabic (ar)
English (en)
Inventor
Hong Lin
Jiri Kasparec
Jerry Leroy Adams
Thomas H Faitg
Neil W Johnson
Mark Mellinger
Xin Peng
Ren Xie
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32727(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA32727B1 publication Critical patent/MA32727B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU L'UN DE SES SELS DE QUALITÉ PHARMACEUTIQUE, OÙ R1, R2, R3, R11, R12, R13, Q, Z ET P SONT TELS QUE DÉCRITS DANS LA PRÉSENTE INVENTION. LES COMPOSÉS SELON LA PRÉSENTE INVENTION PEUVENT ÊTRE EMPLOYÉS DANS LE TRAITEMENT DE CANCERS.
MA33791A 2008-10-27 2011-04-22 Pyrazolylaminopyridines au titre d'inhibiteurs de fak MA32727B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10856808P 2008-10-27 2008-10-27
US17851709P 2009-05-15 2009-05-15
US24243209P 2009-09-15 2009-09-15
PCT/US2009/062163 WO2010062578A1 (fr) 2008-10-27 2009-10-27 Pyrazolylaminopyridines au titre d'inhibiteurs de fak

Publications (1)

Publication Number Publication Date
MA32727B1 true MA32727B1 (fr) 2011-10-02

Family

ID=42132177

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33791A MA32727B1 (fr) 2008-10-27 2011-04-22 Pyrazolylaminopyridines au titre d'inhibiteurs de fak

Country Status (36)

Country Link
US (6) US20110207743A1 (fr)
EP (1) EP2421537B1 (fr)
JP (1) JP5642689B2 (fr)
KR (1) KR101512217B1 (fr)
CN (1) CN102264371B (fr)
AR (1) AR073993A1 (fr)
AU (1) AU2009320144B2 (fr)
BR (1) BRPI0920053B8 (fr)
CA (1) CA2741760C (fr)
CL (1) CL2011000933A1 (fr)
CO (1) CO6361929A2 (fr)
CR (1) CR20110264A (fr)
CY (1) CY1116399T1 (fr)
DK (1) DK2421537T3 (fr)
DO (1) DOP2011000113A (fr)
EA (1) EA021927B1 (fr)
ES (1) ES2539835T3 (fr)
HK (1) HK1161680A1 (fr)
HR (1) HRP20150531T1 (fr)
IL (1) IL212444A (fr)
JO (1) JO3067B1 (fr)
MA (1) MA32727B1 (fr)
MX (1) MX2011004369A (fr)
MY (1) MY161890A (fr)
NZ (1) NZ592477A (fr)
PE (1) PE20110941A1 (fr)
PL (1) PL2421537T3 (fr)
PT (1) PT2421537E (fr)
RS (1) RS54045B1 (fr)
SG (1) SG195608A1 (fr)
SI (1) SI2421537T1 (fr)
SM (1) SMT201500157B (fr)
TW (1) TWI454467B (fr)
UY (1) UY32200A (fr)
WO (1) WO2010062578A1 (fr)
ZA (1) ZA201102892B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
BR112013018565A2 (pt) * 2011-01-26 2016-09-27 Univ Texas combinações
EP2675794B1 (fr) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Inhibiteurs sélectifs de fak
CA2827171C (fr) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Inhibiteurs de fak
CA2840211A1 (fr) * 2011-06-28 2013-01-03 Glaxosmithkline Intellectual Property (No.2) Limited Procede d'administration et de traitement
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
WO2017004192A1 (fr) 2015-06-29 2017-01-05 Verastem, Inc. Compositions thérapeutiques, associations et procédés d'utilisation
CN108948019B (zh) * 2017-05-18 2022-07-08 广东东阳光药业有限公司 黏着斑激酶抑制剂及其用途
WO2019117813A1 (fr) * 2017-12-15 2019-06-20 National University Of Singapore Agents thérapeutiques ciblant une kinase d'adhésion focale pour le traitement du glaucome et de la fibrose
JP2021517589A (ja) 2018-03-12 2021-07-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
US20220040317A1 (en) * 2018-09-27 2022-02-10 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166139A (en) * 1875-07-27 Improvement in dental pluggers
US6316603B1 (en) * 1998-09-08 2001-11-13 Agouron Pharmaceuticals, Inc. Modifications of the VEGF receptor-2 protein and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
PL1660458T3 (pl) * 2003-08-15 2012-07-31 Novartis Ag 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1746096A1 (fr) * 2005-07-15 2007-01-24 4Sc Ag Analogues de 2-arylbenzothiazole utiles comme agents anticancereux
DK2134689T3 (da) * 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
EP2249650A4 (fr) * 2008-02-19 2012-01-11 Glaxosmithkline Llc Anilinopyridines utilisées comme inhibiteurs de fak
JP5551689B2 (ja) * 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物

Also Published As

Publication number Publication date
ZA201102892B (en) 2012-02-29
WO2010062578A1 (fr) 2010-06-03
EP2421537A1 (fr) 2012-02-29
EP2421537A4 (fr) 2012-06-13
DK2421537T3 (da) 2015-06-22
BRPI0920053B8 (pt) 2021-05-25
SMT201500157B (it) 2015-09-07
AU2009320144A1 (en) 2010-06-03
AR073993A1 (es) 2010-12-15
CA2741760C (fr) 2016-02-23
MX2011004369A (es) 2011-05-25
EP2421537B1 (fr) 2015-04-08
JO3067B1 (ar) 2017-03-15
CO6361929A2 (es) 2012-01-20
CY1116399T1 (el) 2017-02-08
US20110269774A1 (en) 2011-11-03
SG195608A1 (en) 2013-12-30
ES2539835T3 (es) 2015-07-06
US9012479B2 (en) 2015-04-21
CN102264371B (zh) 2013-10-02
RS54045B1 (en) 2015-10-30
BRPI0920053B1 (pt) 2019-11-26
IL212444A0 (en) 2011-06-30
US9446034B2 (en) 2016-09-20
SI2421537T1 (sl) 2015-06-30
MY161890A (en) 2017-05-15
KR101512217B1 (ko) 2015-04-15
NZ592477A (en) 2013-01-25
CR20110264A (es) 2011-10-04
AU2009320144B2 (en) 2013-11-21
US20100113475A1 (en) 2010-05-06
CL2011000933A1 (es) 2011-10-21
PL2421537T3 (pl) 2015-08-31
JP5642689B2 (ja) 2014-12-17
TW201028394A (en) 2010-08-01
US20160095841A1 (en) 2016-04-07
PE20110941A1 (es) 2012-02-08
BRPI0920053A2 (pt) 2015-12-15
JP2012506876A (ja) 2012-03-22
DOP2011000113A (es) 2011-07-15
CN102264371A (zh) 2011-11-30
CA2741760A1 (fr) 2010-06-03
UY32200A (es) 2010-05-31
US20150265589A1 (en) 2015-09-24
IL212444A (en) 2015-11-30
EA201170617A1 (ru) 2011-12-30
US20140107131A1 (en) 2014-04-17
HK1161680A1 (en) 2012-08-03
HRP20150531T1 (hr) 2015-06-19
TWI454467B (zh) 2014-10-01
EA021927B1 (ru) 2015-09-30
US20110207743A1 (en) 2011-08-25
KR20110080172A (ko) 2011-07-12
PT2421537E (pt) 2015-07-03

Similar Documents

Publication Publication Date Title
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201170832A1 (ru) Пуриновые соединения
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA201100030A1 (ru) Пиразольные соединения 436
EA200970156A1 (ru) Пиридизиноновые производные
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EA201100503A1 (ru) Глюкозидные производные и их применения
MX2013004004A (es) Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2).
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.